MedPath

Combined Lumbosacral Nerve Block Versus Spinal Anesthesia for Cognitive Function After Hip Prothesis

Not Applicable
Conditions
Cognitive Decline
Interventions
Other: unilateral lumbosacral nerve block
Other: Spinal anesthesia
Other: Placebo at lumbosacral level
Other: Placebo at the spinal anesthesia level
Registration Number
NCT03794427
Lead Sponsor
Makassed General Hospital
Brief Summary

Hip fracture is a potentially devastating event, and serious surgical and medical complications occur frequently especially for elderly patients. Delirium is one of the common complications after hip surgery. Controversy exists regarding the possible impact of type of anesthesia (nerve block versus spinal) upon acute and long-term cognitive decline.

The primary objective is to assess the association between type of anesthesia (nerve block vs. spinal anesthesia) and risk of cognitive decline (CD). The secondary objective is to compare intra-operative hemodynamic changes, use of vasopressor drugs, and use of post-operative analgesics with respect to the type of anesthesia.

Prospective, double blind randomized clinical trial of hip fracture patients who will be assessed for CD pre- and postoperatively, using the Mini Mental State Examination (MMSE). The presence of CD will be determined at follow-up evaluation up to three months after surgery.

Detailed Description

Prospective, double blind randomized clinical trial of hip fracture patients who will be assessed for CD pre- and postoperatively, using the Mini Mental State Examination (MMSE). The presence of CD will be determined at follow-up evaluation up to three months after surgery. Patients undergoing hip surgery will be randomized into two groups. Group 1 will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5) as well as placebo injection (1 ml normal saline) at the spinal anesthesia level (L3-L4 or L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg. Group 2 will receive spinal anesthesia (3 ml of 0.5% bupivacaine) in addition to placebo injection at the sciatic, L3-L4 and L4-L5 levels.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Admitted with a hip fracture (femoral neck, trochanteric or sub-trochanteric)
  • 40 kg in weight and higher
Exclusion Criteria

Patients who are:

  • Uncooperative
  • Considered as moribund by the orthopedic surgeon at admission
  • Alzheimer
  • Severe cognitive impairment (MMSE<18)
  • Absolute contraindication for spinal anesthesia (assessed preoperatively)
  • Allergy to local anesthesia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
unilateral lumbosacral nerve blockunilateral lumbosacral nerve blockSciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
Spinal anesthesiaPlacebo at lumbosacral levelspinal anesthesia will be performed
Spinal anesthesiaSpinal anesthesiaspinal anesthesia will be performed
unilateral lumbosacral nerve blockPlacebo at the spinal anesthesia levelSciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
Primary Outcome Measures
NameTimeMethod
Cognitive decline3 months after operation

Patients' cognitive function will be assessed using the Mini Mental State Examination. The total score ranges between 0 and 30. A total score between 24 and 30 indicates no cognitive impairment. A score between 18 and 23 indicates mild cognitive impairment. A score between 0 and 17 indicates severe cognitive impairment

Secondary Outcome Measures
NameTimeMethod
Intra-operative hemodynamic changesevery 10 minutes intra-operative

Mean arterial pressure (in mmHg) will be recorded through a questionnaire

Trial Locations

Locations (1)

Makassed General Hospital

🇱🇧

Beirut, Lebanon

© Copyright 2025. All Rights Reserved by MedPath